Core Insights - The announcement highlights multiple reports presented at the 2025 ObesityWeek in Atlanta, Georgia, focusing on the efficacy and safety of the company's obesity treatment pipeline [1] - The reports include a complete analysis of the ASC30 oral tablet Phase Ib study, the ASC30 monthly injection Phase Ib study, and preclinical studies of ASC31 and ASC47 combination therapy [1] - The company's proprietary technologies, including AI-assisted drug discovery and ultra-long-acting drug development platforms, are emphasized as key components of their research [1] - The CEO expresses a commitment to advancing clinical development while engaging closely with strategic partners to meet global obesity treatment needs [1]

Core Viewpoint - The company, Gilead Sciences-B (01672.HK), announced multiple reports to be presented at the 2025 ObesityWeek in Atlanta, Georgia, highlighting the efficacy and safety of its obesity treatment pipeline, including ASC30, ASC31, and ASC47 [1] Group 1 - The reports will include a complete analysis of the Phase Ib study of ASC30, a monthly injection study of ASC30, and preclinical studies of ASC31 and ASC47 combination therapy [1] - The presentations demonstrate the promising efficacy and safety characteristics of Gilead's small molecules and peptides in the obesity treatment pipeline [1] - The CEO, Dr. Wu Jinzi, emphasized the importance of strategic partnerships to better meet the treatment needs of global obesity patients while advancing the clinical development of ASC30, ASC31, and ASC47 [1]